The Phase 0 study of itraconazole in early-stage non-small cell lung cancer (NSCLC) aims to explore its pharmacodynamic effects on tumor angiogenesis and the Hedgehog pathway. Given the high prevalence of NSCLC and the limited treatment options available for early-stage patients, this study could position itraconazole as a novel therapeutic option, particularly in combination with surgical resection. The findings may enhance the competitive landscape for NSCLC treatments, especially against existing anti-angiogenic therapies. Investors and stakeholders should consider the implications of these results on market positioning and potential partnerships for further development.